Plain-English translation of NCT06033248 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a novel approach to lung cancer detection using a special animal biosensor platform—essentially trained rats that can detect unique chemical signatures in urine samples from people with lung cancer. The goal is to see whether this simple urine test can accurately identify non-small cell lung cancer without needing invasive procedures like biopsies. Researchers believe this could become a faster, easier way to catch lung cancer early.
Current lung cancer screening often requires CT scans, biopsies, or other invasive tests that can be uncomfortable and time-consuming. This trial exists to determine whether a simple urine test using animal biosensors could provide an accurate, non-invasive way to detect lung cancer early, when treatment is most effective.
You likely qualify if…
You likely don't qualify if…
Participation is straightforward: you'll provide a urine sample, which researchers will test using the animal biosensor platform. Depending on which group you're in, you may be enrolled in Phase I (if you have diagnosed or ruled-out lung cancer) or Phase II (if you have suspected but undiagnosed lung cancer). The study involves a single visit to provide your sample—there are no medications to take or ongoing appointments required.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States